First-line treatment for advanced lung cancer with specific genetic mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Vebreltinib combined with PLB1004 as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have specific genetic mutations (EGFRm+ and MET+). The study is multicenter, randomized, and open-label, focusing on patients with untreated EGFR mutations (exon 19 deletion or L858R) and MET overexpression. Participants will be monitored for treatment response and safety outcomes over the course of the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent document.
2. Aged at least 18 years old.
3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV).
4. Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .
5. At least one measurable lesion as defined by RECIST V1.1.
6. ECOG performance status 0 to 1.

Exclusion Criteria:

1. There are mutations of ALK or ROS1.
2. Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
3. Pregnant or nursing women.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Yi long Wu, MD — Guangdong Provincial People's Hospital
• Study coordinator: Liang Lin
• Email: linliang@avistonebio.com
• Phone: 08-10-84148931

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vebreltinib plus furmonertinib in EGFR-mutated NSCLC with high PD-L1

  This study tests whether combining vebreltinib with furmonertinib can help people with advanced NSCLC that has EGFR mutations and very high PD-L1 expression.

  Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University · Nanchang, Jianxi · NCT07655622

• Vebreltinib plus platinum-based doublet chemotherapy for MET-positive non-squamous NSCLC

  This trial will test whether adding the oral drug vebreltinib to standard platinum-based doublet chemotherapy helps people with MET-positive, previously untreated locally advanced or metastatic non-squamous NSCLC.

  Recruiting Phase 3 Beijing Pearl Biotechnology Limited Liability Company · Beijing, Beijing Municipality and 1 other locations · NCT06930794

• Combining Vebreltinib and PLB1004 for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs, Vebreltinib and PLB1004, to see if they can help people with advanced lung cancer who have certain genetic changes and haven't responded to previous treatments.

  Recruiting Phase 1/2 Avistone Biotechnology Co., Ltd. · Shanghai, Shanghai Municipality · NCT06343064

• Testing PLB1001 in lung cancer patients with a specific mutation

  This study is testing a new drug called PLB1001 to see if it helps people with a specific type of lung cancer that has a MET exon 14 mutation.

  Recruiting Phase 3 Beijing Pearl Biotechnology Limited Liability Company · Guangzhou, Guangdong · NCT05989542

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.